Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) have received a consensus rating of "Moderate Buy" from the nine brokerages that are covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among analysts that have covered the stock in the last year is $94.57.
LMAT has been the subject of several analyst reports. Barrington Research boosted their target price on LeMaitre Vascular from $92.00 to $93.00 and gave the stock an "outperform" rating in a research note on Friday, November 1st. Oppenheimer reiterated an "outperform" rating and issued a $93.00 price target (up from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. StockNews.com cut shares of LeMaitre Vascular from a "buy" rating to a "hold" rating in a report on Friday, December 13th. Finally, Cantor Fitzgerald initiated coverage on shares of LeMaitre Vascular in a report on Tuesday, October 15th. They issued a "neutral" rating and a $96.00 target price for the company.
Check Out Our Latest Analysis on LeMaitre Vascular
Insider Transactions at LeMaitre Vascular
In related news, Director Bridget A. Ross sold 3,750 shares of LeMaitre Vascular stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $101.47, for a total value of $380,512.50. Following the sale, the director now directly owns 2,278 shares in the company, valued at $231,148.66. The trade was a 62.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 10.79% of the company's stock.
Institutional Investors Weigh In On LeMaitre Vascular
Several institutional investors have recently made changes to their positions in the stock. NBC Securities Inc. increased its holdings in shares of LeMaitre Vascular by 73.2% in the 3rd quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier's stock valued at $40,000 after purchasing an additional 183 shares in the last quarter. USA Financial Formulas purchased a new position in LeMaitre Vascular in the third quarter valued at about $60,000. GAMMA Investing LLC lifted its position in shares of LeMaitre Vascular by 34.3% during the 3rd quarter. GAMMA Investing LLC now owns 736 shares of the medical instruments supplier's stock valued at $68,000 after acquiring an additional 188 shares during the period. Canada Pension Plan Investment Board purchased a new stake in shares of LeMaitre Vascular during the 2nd quarter worth approximately $82,000. Finally, Acadian Asset Management LLC acquired a new stake in shares of LeMaitre Vascular in the 2nd quarter worth approximately $104,000. 84.64% of the stock is currently owned by hedge funds and other institutional investors.
LeMaitre Vascular Stock Performance
Shares of NASDAQ LMAT traded up $0.83 during trading on Friday, reaching $99.06. The stock had a trading volume of 116,296 shares, compared to its average volume of 149,427. The company has a market cap of $2.23 billion, a P/E ratio of 54.13, a PEG ratio of 2.07 and a beta of 0.96. LeMaitre Vascular has a fifty-two week low of $56.04 and a fifty-two week high of $109.58. The business's 50-day moving average price is $98.48 and its 200-day moving average price is $91.80.
LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.05. The company had revenue of $54.82 million during the quarter, compared to the consensus estimate of $53.50 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. LeMaitre Vascular's revenue was up 15.6% compared to the same quarter last year. During the same period in the previous year, the company posted $0.33 EPS. Analysts forecast that LeMaitre Vascular will post 1.94 EPS for the current fiscal year.
LeMaitre Vascular Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Thursday, December 5th. Stockholders of record on Thursday, November 21st were paid a $0.16 dividend. This represents a $0.64 annualized dividend and a dividend yield of 0.65%. The ex-dividend date was Thursday, November 21st. LeMaitre Vascular's dividend payout ratio (DPR) is presently 34.97%.
About LeMaitre Vascular
(
Get Free ReportLeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.
Read More
Before you consider LeMaitre Vascular, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LeMaitre Vascular wasn't on the list.
While LeMaitre Vascular currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
